Based on the Redhill Biopharma Ltd stock forecast from 0 analysts, the average analyst target price for Redhill Biopharma Ltd is not available over the next 12 months. Redhill Biopharma Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Redhill Biopharma Ltd is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Redhill Biopharma Ltd’s stock price was USD 2.07. Redhill Biopharma Ltd’s stock price has changed by -23.33% over the past week, -19.14% over the past month and -78.49% over the last year.
No recent analyst target price found for Redhill Biopharma Ltd
No recent average analyst rating found for Redhill Biopharma Ltd
Company Overview Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. Read Less
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea i...Read More
Frequently Asked Questions About Redhill Biopharma Ltd (RDHL) Stock
Stock Target Advisor's fundamental analysis for Redhill Biopharma Ltd's stock is Slightly Bearish.
Unfortunately we do not have enough data on RDHL's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on RDHL's stock to indicate what its average analyst target is.
RDHL stock's Price/Earning ratio is 0.09.
Our analysis grades RDHL stock's Price / Earning ratio at A-. This means that RDHL stock's Price/Earning ratio is above 8.999999999999996% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this RDHL may be undervalued for its sector.
The last closing price of RDHL's stock was USD 2.07.
The most recent market capitalization for RDHL is USD 3.88M.
Unfortunately we do not have enough analyst data on RDHL's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Redhill Biopharma Ltd's stock.
As per our most recent records Redhill Biopharma Ltd has 53 Employees.
Redhill Biopharma Ltd's registered address is 21 Ha?arba?a Street, Tel Aviv, Israel, 6473921.
You can get more information about it from Redhill Biopharma Ltd's website at https://www.redhillbio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Redhill Biopharma Ltd (RDHL) Stock
Stock Target Advisor's fundamental analysis for Redhill Biopharma Ltd's stock is Slightly Bearish.
Unfortunately we do not have enough data on RDHL's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on RDHL's stock to indicate what its average analyst target is.
RDHL stock's Price/Earning ratio is 0.09.
Our analysis grades RDHL stock's Price / Earning ratio at A-. This means that RDHL stock's Price/Earning ratio is above 8.999999999999996% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this RDHL may be undervalued for its sector.
The last closing price of RDHL's stock was USD 2.07.
The most recent market capitalization for RDHL is USD 3.88M.
Unfortunately we do not have enough analyst data on RDHL's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Redhill Biopharma Ltd's stock.
As per our most recent records Redhill Biopharma Ltd has 53 Employees.
Redhill Biopharma Ltd's registered address is 21 Ha?arba?a Street, Tel Aviv, Israel, 6473921.
You can get more information about it from Redhill Biopharma Ltd's website at https://www.redhillbio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RDHL !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
